1 The eects of b 3 -adrenergic stimulation were studied on the L-type Ca 2+ channel in single myocytes from rat portal vein using the whole-cell mode of the patch-clamp technique. 2 Reverse transcription-polymerase chain reaction showed that b 1 -, b 2 -and b 3 -adrenoceptor subtypes were expressed in rat portal vein myocytes. Application of both propranolol (a nonselective b 1 -and b 2 -adrenoceptor antagonist) and SR59230A (a b 3 -adrenoceptor antagonist) were needed to inhibit the isoprenaline-induced increase in L-type Ca 2+ channel current. 3 L-type Ca 2+ channels were stimulated by CGP12177A (a b 3 -adrenoceptor agonist with potent b 1 -and b 2 -adrenoceptor antagonist property) in a manner similar to that of isoprenaline. The CGP12177A-induced stimulation of Ca 2+ channel current was blocked by SR59230A, cyclic AMPdependent protein kinase inhibitors, H-89 and Rp 8-Br-cyclic AMPs, but was unaected by protein kinase C inhibitors, GF109203X and 19-31 peptide. This stimulation was mimicked by forskolin and 8-Br-cyclic AMP. In the presence of okadaic acid (a phosphatase inhibitor), the b 3 -adrenoceptorinduced stimulation was maintained after withdrawal of the agonist. 4 The b 3 -adrenoceptor stimulation of L-type Ca 2+ channels was blocked by a pretreatment with cholera toxin and by the intracellular application of an anti-Ga s antibody. This stimulation was unaected by intracellular infusion of an anti-Gb com antibody and a bARK 1 peptide. 5 These results show that activation of b 3 -adrenoceptors stimulates L-type Ca 2+ channels in vascular myocytes through a Ga s -induced stimulation of the cyclic AMP/protein kinase A pathway and the subsequent phosphorylation of the channels.
Introduction
Previous data have reported that b-adrenergic activation stimulates L-type Ca 2+ channels in vascular and visceral smooth muscles (Fukumitsu et al., 1990; Loirand et al., 1992 , Muraki et al., 1993 . Several reports support a stimulatory eect of the cyclic AMP/protein kinase A (PKA) pathway on L-type Ca 2+ channels in vascular myocytes (Shi & Cox, 1995; Tewari & Simard, 1994; Ruiz-Velasco et al., 1998) . These results are in contrast with other data indicating that isoprenaline and cyclic AMP exert a transient increase followed by a decrease in L-type Ca 2+ channel activity (Xiong et al., 1994; Xiong & Sperelakis, 1995) . The stimulatory eect of b-adrenergic receptor activation has been proposed to depend on a direct modulation of L-type Ca 2+ channels by the activated G s protein whereas the inhibitory eect has been attributed to G s activation of adenylyl cyclase and the subsequent phosphorylation of the Ca 2+ channel by PKA (Xiong & Sperelakis, 1995) . However, there are increasing evidence that three or four b-adrenoceptor subtypes may exist in dierent cell types including heart and visceral smooth muscle (Kaumann, 1997) , so that b-adrenergic stimulation cannot be considered as a single mechanism as long as badrenoceptors have not been identi®ed in the studied cells. b 3 -adrenoceptors have been identi®ed in adipocytes in which they are predominantly expressed (Emorine et al., 1989) but also in cardiac and smooth muscles (Kaumann, 1997; Anthony et al., 1998) . Activation of b 3 -adrenoceptors has been shown to induce negative inotropic eect in human heart (Gauthier et al., 1996) and relaxation in visceral smooth muscle (Fujimura et al., 1999) , but the cellular mechanisms activated by these receptors in vascular myocytes have not been elucidated.
In the present study, we identi®ed by RT ± PCR the mRNAs corresponding to b 1 -, b 2 -and b 3 -adrenoceptor subtypes and demonstrated the existence of a b 3 -adrenoceptor activatedstimulation of L-type Ca 2+ channels in rat portal vein myocytes. We show that the transduction pathway activated by b 3 -adrenoceptors is mediated through a Ga s -induced stimulation of the cyclic AMP/PKA pathway and the subsequent phosphorylation of L-type Ca 2+ channels.
Methods
The investigation conforms with the European Community guiding principles in the care and use of animals (86/609/ CEE, CE O J n o L358, 18 December 1986) and the French decree n o 87/748 of October 19, 1987 (J O ReÂ publique FrancË aise, 20 October 1987 . Authorizations to perform animal experiments according to this decree were obtained from the French MinisteÁ re de l'Agriculture et de la PeÃ che.
Cell preparation
Isolated myocytes from rat portal vein were obtained by enzymatic dispersion, as described previously (LepreÃ tre et al., 1994) . Cells were seeded at density of *10 3 cells mm 72 on glass slides and maintained in short-term primary culture (2 ± 36 h) in M199 containing 5% foetal calf serum, 2 mM glutamine, 1 mM pyruvate, 20 u ml 71 penicillin and 20 mg ml 71 streptomycin.
Membrane current measurement
Voltage-clamp and membrane current recordings were performed with a standard patch-clamp technique using an EPC-7 ampli®er (List, Darmstadt-Eberstadt, Germany). Whole-cell recordings were performed with patch pipettes having resistances of 2 ± 4 MO. Membrane potential and membrane currents were stored and analysed using a PC computer (P-clamp system, Axon Instruments, Foster City, CA, U.S.A.). Ba 2+ current density is expressed as peak current amplitude per capacitance unit (in pA/pF). All experiments were performed at 30+18C. Results are expressed as means +s.e.mean. Signi®cance was tested by Student's t-test. P values 40.05 were considered as signi®cant.
Solutions
The physiological solution used to record Ba 2+ currents contained (in mM): NaCl 130, KCl 5.6, MgCl 2 1, BaCl 2 5, glucose 11, HEPES 10, pH 7.4 with NaOH. The basic pipette solution contained (in mM): CsCl 130, EGTA 10, ATPNa 2 5, GTP 0.1, MgCl 2 2, HEPES 10, pH 7.3, with CsOH. Isoprenaline and CGP12177A were extracellularly applied to the recorded cell by pressure ejection from a glass pipette.
RNA puri®cation and reverse transcription-polymerase chain reaction (PCR)
Total RNA was extracted from about 500 cells dissociated from rat portal vein and detrusor muscles by using RNeasy mini kit (Qiagen, Hilden, Germany) and following the instructions of the supplier. The reverse transcription reaction was performed using Sensiscript RT kit (Qiagen, Hilden, Germany). Brie¯y, total RNA was ®rst incubated with random primers (Promega, CharbonnieÁ res, France) at 658C for 5 min and cooled down 60 min at 378C. The resulting cDNA was stored at 7208C. PCR was performed with 1 ml of cDNA, 1.25 units of HotStartTaq DNA polymerase (Qiagen), 0.5 mM of each primer and 200 mM of each deoxynucleotide triphosphate, in a ®nal volume of 50 ml. The PCR conditions were 958C for 15 min for HotStartTaq activation, then 35 cycles were performed as follows: 948C for 1 min, 558C (b 1 -and b 2 -adrenoceptors) or 628C (b 3 -adrenoceptor) for 1.5 min and 728C for 1 min. At the end of PCR, samples were kept at 728C for 10 min for ®nal extension before being stored at 48C. Reverse transcription and PCR were performed with a thermal cycler (Techne, Cambridge, U.K.). Ampli®cation products were separated by electrophoresis (2% agarose gel) and visualized by ethidium bromide staining. Gels were photographed with EDAS 120 and analysed with KDS1D 2.0 software (Kodak Digital Science, Paris, France). Sense (s) and antisense (as) primer pairs speci®c for b 1 -, b 2 and b 3 -adrenoceptors were designed on the known cloned rat receptor sequences deposited in GenBank (accession numbers D00634, X17607 and S73473 for b 1 -, b 2 -and b 3 -adrenoceptors, respectively) with Lasergene software (DNASTAR, Madison, WI, U.S.A.). The nucleotide sequences and the length of the expected PCR products (in parentheses) for each primer pair were respectively: b 1 -adrenoceptor (s) TC GT G T GC A C CG T G TG G G CC , (as) AG GA AA CG GC GC TC GC AG CT (264 bp); b 2 -adrenoceptor (s) GC CT GC TG AC CA AG AA TA AG, (as) CC CA TC CT GC TC CA CC TG G (328 bp); b 3 -adrenoceptor (s) AC CT TG GC GC TG AC TG G, (as) AT GG GC GC AA AC GA CA C (229 bp).
Chemicals and drugs
Isoprenaline, propranolol, prazosin and rauwolscine were from Sigma (Saint Quentin Fallavier, France). Forskolin, 8-Br-cyclic AMP, Rp-8-Br-cyclic AMPs, H-89, 19-31 peptide and cholera toxin (CTX) were from Calbiochem (Meudon, France). Phorbol ester 12,13-dibutyrate and 4a-phorbol 12,13-dibutyrate were from LC Laboratories (Woburn, MA, U.S.A.). The protein kinase C (PKC) inhibitor, GF109203X, was a gift from Glaxo (Les Ulis, France). CGP12177A was from RBI (Natick, MA, U.S.A.). SR59230A (3-(2-ethylphenoxy)-1[(1S)-1,2,3,4-tetrahydronapth-1-ylaminol] -(2S)-propanolol-oxalate) was from Sano® (Milano, Italy). M199 medium was from Flow Laboratories (Puteaux, France). Streptomycin, penicillin, glutamine and pyruvate were from Gibco (Paisley, U.K.). Rabbit anti-Ga s subunit antibody (371732) raised to the carboxyl-terminal animo acids, RMHLRQYELL, of Ga s was from Calbiochem. Rabbit anti-Gb com antibody (SC 378) raised to the carboxyl-terminal amino acids, TDDGMA-VATGSWDSFLKIWN, of Gb 1 subunit was from Santa-Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Peptides corresponding to the Gbg binding domain of b-adrenergic receptor kinase-1 or to a region outside the Gbg binding site (Viard et al., 1999) were synthetized by Genosys (Cambridge, U.K.). PCR primers were synthetized by Eurogentec (Seraing, Belgium). Molecular-weight marker, HinfI, was from Promega (CharbonnieÁ res, France).
Results

Eects of isoprenaline on voltage-dependent Ba
2+ current
Inward currents were elicited every 20 s in single myocytes bathed in 5 mM BaCl 2 solution by 200 ms depolarization to +10 mV from a holding potential of 740 mV and they gradually increased in size over 2 ± 3 min in almost all cells, as previously reported (Viard et al., 1999) . After the amplitude of inward current became steady application of 10 mM isoprenaline (in the continuous presence of 10 nM prazosin and 10 nM rauwolscine to inhibit a 1 -and a 2 -adrenoceptors, LepreÃ tre et al., 1994) resulted in an increase in Ba 2+ current reaching 39+8% (n=5) within 3 ± 4 min ( Figure 1 ). Under both conditions (with or without isoprenaline), the recorded Ba 2+ currents were completely blocked by 1 mM oxodipine or isradipine (data not shown). After a 10 min pre-treatment with either 1 mM propranolol (a non-selective b 1 -and b 2 -adrenoceptor antagonist) or 0.1 mM SR59230A alone (a b 3 -adrenoceptor antagonist, Manara et al., 1996) , the isoprenaline-induced stimulation of Ba 2+ current was not signi®cantly aected ( Figure 1B ). In contrast, application of both compounds inhibited the stimulation of the Ba 2+ current evoked by 10 mM isoprenaline ( Figure 1A ,B). Figure 1C illustrates the inhibitory eect of increasing concentrations of SR59230A in the absence or in the presence of 1 mM propranolol. It appears that the inhibitory concentration-response curve for SR59230A was shifted to lower concentrations in the presence of propranolol, as the SR59230A concentration corresponding to half-maximal inhibition decreased from 1.2 mM to 14 nM.
In order to identify the b-adrenoceptors potentially involved in the eects of isoprenaline, mRNA puri®ed from rat portal vein myocytes was reversibly transcribed into cyclic DNA, and a fragment of cyclic DNA of each receptor subtype was ampli®ed using subtype-speci®c primers for the PCR. As illustrated in Figure 2 , products of expected sizes corresponding to b 1 -, b 2 -and b 3 -adrenoceptor mRNAs were detected in rat portal vein and detrusor muscle (used as a positive control, Seguchi et al., 1998) . These results suggest that the three badrenoceptor subtypes are involved in the stimulation of Ba 2+ current through independent transduction pathways which, however, present a common step since their eects are not additive. Furthermore, it appears that SR59230A is a speci®c antagonist of b 3 -adrenoceptors at concentrations lower than 100 nM.
Stimulation of Ba
2+ current by the selective b 3 agonist CGP12177A
In the following experiments, CGP12177A was used as a b 3 -adrenergic agonist and 1 mM propranolol, 10 nM prazosin and 10 nM rauwolscine were continuously added to the perfusion solution. Stimulation of Ba 2+ current was detectable with 10 nM CGP12177A and increased with the concentration of CGP12177A to reach a maximum with 10 mM CGP12177A ( Figure 3A ,B). The maximal stimulation of Ba 2+ current in the presence of 10 mM CGP12177A was 43+4% (n=25), not signi®cantly dierent from that obtained with 10 mM isoprenaline ( Figure 3B ). The concentration of CGP12177A and isoprenaline producing a half-maximal stimulation of Ba 2+ current were 0.14 and 1.35 mM, respectively ( Figure 3B ). CGP12177A-induced stimulation of Ba 2+ current was concentration-dependently inhibited by SR59230A with a halfmaximal inhibition obtained at 18 nM ( Figure 3C ). As illustrated by the current-voltage relationship ( Figure 4A ), the 
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2+ channel stimulation by beta-3 adrenoceptors 1499 P. Viard et al maximal Ba 2+ current was increased by 10 mM CGP12177A without any change in the voltage threshold, the potential for the maximal current, and the extrapolated reversal potential. Steady-state inactivation of the Ba 2+ current was examined with a two-pulse protocol ( Figure 4B) . A test pulse to +10 mV (V 2 ) from a holding potential of 740 mV was preceded by a prepulse (V 1 ) of 20 s duration and of variable amplitude (760 to 720 mV). For each prepulse, the amplitude of the test current was taken as an index of the remaining activatable channels. Relative availability was expressed by plotting the test current against the prepulse potential value. The amplitude of the test current was expressed as a fraction of the current obtained at the most negative prepulse. As shown in Figure 4B , the curves obtained in the absence and presence of 10 mM CGP12177A were superimposed. Since the Ba 2+ currents in cells stimulated by CGP12177A appeared to be slightly more enhanced at negative potentials than at positive potentials, we calculated the conductance (G) by dividing the peak Ba current at each negative potential tested by the driving force (V-V rev ). The normalized conductance (G/G max ) is plotted as a function of membrane potential in Figure 4C . In control conditions we found a half-activation potential of 714.0+2.0 mV (n=4). In the presence of 10 mM CGP12177A, the half-activation potential was not signi®cantly modi®ed (716.5+2.5 mV, n=4, P40.05). Taken together, these results indicate that CGP12177A stimulates L-type Ca 2+ channels without aecting the gating properties of these channels.
Transduction pathway activated by b 3 -adrenoceptors
Modulation of L-type Ca 2+ channels in vascular myocytes by b-adrenoceptor activation is believed to involve the cyclic AMP/PKA pathway through phosphorylation of channel subunits by PKA (Ishikawa et al., 1993) and/or a possible direct modulation of the channel activity by a subunits of Gs protein (Xiong et al., 1995) .
To elucidate the mechanism of stimulation of Ba 2+ current by CGP12177A, we applied forskolin, a direct activator of adenylyl cyclase. Forskolin (5 mM) increased the Ba 2+ current by 40+6% (n=10) within 4 ± 5 min ( Figure 5A,B) . Similarly, 8-Br-AMPc (0.3 mM), applied extracellularly, stimulated the Ba 2+ current by 35+6% (n=5; Figure 5A ) indicating that activation of PKA may stimulate L-type Ca 2+ channels in vascular myocytes. To evaluate whether PKA is involved in the intracellular pathway activated by b 3 -adrenoceptors, we tested the eects of PKA inhibitors (H-89 and Rp 8-Br-cyclic AMPs) on the stimulation of Ba 2+ current evoked by CGP12177A. Superfusion of cells with H-89 (0.1 mM) or Rp 8-Br-cyclic AMPs (10 mM) for 10 ± 15 min did not change the peak Ba 2+ current in control cells (data not shown) nor aect the stimulatory response of 1 mM phorbol dibutyrate, an activator of PKC (control: 37+4%, n=4; in the presence of H-89: 42+4%, n=4; Figure 5B ). In contrast, the stimulation of Ba 2+ current evoked by forskolin, 8-Br-AMPc (not shown) or CGP12177A was inhibited by H-89 ( Figure 5B ) and Rp 8-Brcyclic AMPs (not shown), suggesting that PKA is involved in the stimulation of Ca 2+ channel activity by b 3 -adrenergic agonist. To ensure that the stimulation of Ba 2+ current was mediated by a phosphorylation of L-type Ca 2+ channels, we applied a protein phosphatase inhibitor, okadaic acid, before stimulation with CGP12177A or forskolin. Okadaic acid (5 mM) by itself had no signi®cant eect on the Ba 2+ current density when applied for 10 ± 15 min (control: 8.1+0.6 pA/pF; in the presence of okadaic acid: 8.9+0.7 pA/pF, n=5) in agreement with previous data on L-type Ca 2+ channels (Chahine et al., 1996) . In control conditions, stimulation of the Ba 2+ current by 10 mM CGP12177A or 5 mM forskolin was maximal within 3 ± 4 min. After withdrawal of the stimulating substances, the Ba 2+ current returned to its control value within 4 ± 5 min ( Figure 6A ± C) . In the presence of 5 mM okadaic acid, the CGP12177A-induced increase in Ba 2+ current was similar to that obtained in control conditions but persisted after wash-out of CGP12177A ( Figure 6B,C) . Similar results were obtained with forskolin (not shown). These results support the idea that a phosphorylation mechanism is involved in the eects of CGP12177A and forskolin on L-type Ca 2+ channels.
To identify the G protein coupling the b 3 -adrenoceptors to adenylyl cyclase we used cholera toxin (CTX) which ADP ribosylates G s proteins, leading to their permanent activity. Cells were incubated in a culture medium containing 160 ng ml 71 CTX for 20 h. This pretreatment suppressed the CGP12177A-induced stimulation of Ba 2+ current ( Figure 7A ) whereas it did not aect the clonidine-induced stimulation of Ba 2+ current (control: 41+5%, n=5; CTX-pre-treated cells: 40+6%, n=5) which has been demonstrated to depend on activation of a G i protein (LepreÃ tre et al., 1995) . Antibodies directed against the carboxyl terminus of the a subunits of G proteins have been shown to be useful tools for identifying transduction couplings. When a carboxyl-terminal anti-Ga s antibody was added to the basic pipette solution for 4 min, the CGP12177A-induced stimulation of Ba 2+ current was concentration-dependently inhibited, with maximal inhibition obtained at 10 mg ml 71 anti-Ga s antibody ( Figure 7B ,C). Intracellular application of the anti-Ga s antibody inactivated by heating at 958C for 30 min did not signi®cantly aect the CGP12177A-induced stimulation of Ba 2+ current ( Figure 7B ). These results indicate that the G s protein transduces the signal for stimulation of Ca 2+ channels in response to activation of b 3 -adrenoceptors.
The anti-Ga s antibody, however, cannot distinguish whether a or bg subunits interact with adenylyl cyclase. Therefore, intracellular infusion of either an anti-Gb com antibody or a peptide corresponding to a fragment of bARK 1 was used to bind Gbg subunits and to block activation of eectors. Applications of bARK 1 peptide and anti-Gb com antibody had no signi®cant eects on the Ba 2+ current density in non-stimulated myocytes. The mean Ba 2+ current density was 8.5+0.5 pA/pF in control conditions (n=21), 7.8+0.7 pA/pF in the presence of 10 mM bARK 1 (n=11) and 7.6+0.6 pA/pF in the presence of 10 mg ml 71 anti-b com antibody for 5 ± 7 min (n=9). As shown in Figure 8A , 10 mg ml 71 anti-Gb com antibody or 10 mM bARK 1 peptide (corresponding to the Gbg binding region of bARK 1 , Nair et al., 1995; Stehno-Bittel et al., 1995) had no signi®cant eects on CGP12177A-induced stimulation of Ba 2+ current (control: 40+3%, n=8; in the presence of bARK 1 : 43+4%, n=5, or anti-Gb com antibody: 41+4%, n=5). In contrast, in the same cell batches, the angiotensin II-induced stimulation of Ba 2+ current was selectively inhibited by both the anti-Gb com antibody and the bARK 1 peptide ( Figure 8B ; control: 44+4%, n=10; in the presence of bARK 1 : 2+1%, n=5, or anti-Gb com antibody: 3+2%, n=5, P50.05). Taken together, these results suggest that Gbg subunits are not involved in the b 3 -adrenergic stimulation of adenylyl cyclase in vascular myocytes.
We have previously shown that the vascular L-type Ca 2+ channels may be stimulated by PKC-dependent mechanisms (LepreÃ tre et al., 1994; Viard et al., 1999) . Stimulation of Ba 2+ current evoked by 0.1 mM PDBu was completely blocked by PKC inhibitors, i.e. external application of 1 mM GF109203X ( Figure 9A,B) or infusion of 1 mM 19 ± 31 peptide. Both GF109203X and 19 ± 31 peptide had no direct eects on the control Ba 2+ current activated by membrane depolarization (data not shown) as well as on the stimulation of Ba 2+ current evoked by forskolin and CGP12177A ( Figure 9A,B) . In addition, simultaneous applications of both 0.1 mM PDBu and 5 mM forskolin resulted in a further increase in Ba 2+ current. This stimulatory eect is higher than that obtained with PDBu or CGP12177A alone ( Figure 9B ) and suggests an additive eect of PKC and PKA on L-type Ca 2+ channel activity. These results con®rm that a PKC-dependent pathway does not mediate the b 3 -adrenergic-induced stimulation of Ca 2+ channels. 
Discussion
The results of the present study indicate that in vascular myocytes: (1) b 1 -, b 2 -and b 3 -adrenoceptor mRNAs are expressed, as identi®ed by RT ± PCR; (2) the stimulatory eect of the b 3 -adrenoceptor agonist CGP12177A on L-type Ca 2+ channels is selectively prevented by SR59230A (the b 3 -adrenoceptor antagonist); (3) the CGP12177A-induced stimulation of Ca 2+ channels is blocked by cyclic AMP dependent protein kinase inhibitors, H-89 and Rp 8-Br-cyclic AMPs, but not by PKC inhibitors, GF109203X and 19 ± 31 peptide. This stimulation was mimicked by forskolin and 8-Br-AMPc. In the presence of okadaic acid, inhibition of recovery after withdrawal of b 3 -adrenoceptor agonist and forskolin suggests that phosphorylation plays a major role on L-type Ca 2+ channel modulation; (4) the b 3 -adrenoceptor stimulation of L-type Ca 2+ channels was removed by a pretreatment with CTX and by the intracellular application of an anti-Ga s antibody but was unaected by intracellular infusion of an anti-Gb com antibody and a bARK 1 peptide. These observations indicate that the transduction coupling activated by b 3 -adrenoceptors involves a Ga s -induced stimulation of the cyclic AMP/PKA pathway leading to phosphorylation and subsequent activation of L-type Ca 2+ channels. The b 3 -adrenoceptors have been cloned and sequenced in several species including rat and human (Strosberg, 1997) . Recent studies have suggested the existence of putative b 4 -adrenoceptors which have not been cloned and sequenced up to now (Kaumann et al., 1998) . However, since these putative b 4 -adrenoceptors have been shown to be insensitive to SR59230A (Galitzky et al., 1997) , our results showing a complete inhibition with SR59230A support the idea that only b 3 -adrenoceptors mediate the CGP12177A-induced stimulation of L-type Ca 2+ channels in vascular myocytes. Activation of the G s /PKA pathway by b 3 -adrenoceptors has been previously reported in rodent adipocytes (Strosberg, 1997) . Although it is generally accepted that a subunits of G s protein play an important role in regulation of L-type Ca 2+ channels in cardiac and smooth muscles during b-adrenergic stimulation, the signalling pathways underlying the modulation of L-type Ca 2+ channels by activated G s proteins remain controversial. In cardiac myocytes, the b-adrenergic-induced stimulation of Ca 2+ channels is essentially via activation of adenylyl cyclase and subsequent phosphorylation of the channel (McDonald et al., 1994) . In addition, a direct G protein activation of Ca 2+ channels has been also proposed in the heart in response to badrenergic stimulation (Yatani et al., 1987) . In rabbit portal vein myocytes, intracellular application of activated Ga s subunits mimics the stimulatory eect of isoprenaline, and this eect has been interpreted as the result of a direct action of G s protein on L-type Ca 2+ channels (Xiong & Sperelakis, 1995) . However, recent reports have shown that 8-Br-cyclic AMP and the catalytic subunit of PKA signi®cantly increased peak Ba 2+ currents, and their eects could be blocked by PKA inhibitors (Ruiz-Velasco et al., 1998) . In the present study, the b 3 -adrenoceptor-induced stimulation of Ba 2+ current was entirely blocked by H-89 and Rp 8-Br-cyclic AMPs, inhibitors of PKA, and by intracellular infusion of the anti-Ga s antibody. In addition, application of okadaic acid, a protein phosphatase inhibitor, suppressed the CGP12177A-and forskolin-induced recovery of Ba 2+ current after withdrawal of the stimulating substances. These results support the idea that the activated a s subunits of G s proteins elicit their stimulatory eect through the cyclic AMP/PKA pathway and the subsequent phosphorylation of L-type Ca 2+ channels. In addition to G s protein, b 3 -adrenoceptors have been shown to interact with G i/o proteins in adipocytes (Chaudhry et al., 1994) and human cardiac cells (Gauthier et al., 1996) . Recently, it has been demonstrated that the human b 3 -adrenoceptor may activate the mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) 1 and 2 through G i/o protein and phosphatidylinositol-3 kinase 
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2+ channel stimulation by beta-3 adrenoceptors 1503 P. Viard et al (PI3K) (Gerhardt et al., 1999) . Moreover, the isoprenalineinduced activation of MAPK has been reported to involve the Gbg dimers derived from G i/o protein (Crespo et al., 1995) . Using an anti-Gb com antibody and a bARK 1 -derived Gbg binding peptide, we have reported that the bg dimer from G 13 is responsible for the transduction pathway during angiotensin II-induced stimulation of L-type Ca 2+ channels . Intracellular infusion of puri®ed Gbg proteins has been shown to stimulate the activity of L-type Ca 2+ channels; this eect is largely inhibited by PKC inhibitors but remains insensitive to PKA inhibitors (Viard et al., 1999) . In contrast, we show here that the b 3 -adrenoceptor-induced stimulation of Ba 2+ current is removed by H-89 but not aected by PKC inhibitors and after intracellular infusion of an anti-Gb com antibody or a bARK 1 peptide, which act as Gbg scavengers. Thus, our results suggest that in vascular myocytes only the a subunits of G s may play a role in the regulation of L-type Ca 2+ channels during b 3 -adrenoceptor activation. Although dierent combinations of b and g subunits of G proteins may have similar actions on Ca 2+ channels (Dolphin, 1998) , recent data have shown that activation of MAPK/ERK and inhibition of adenylyl cyclases V and VI appear to be Gb isoform speci®c (Gb 1 being more ecient than Gb 5 ) (Zhang et al., 1996; Bayewitch et al., 1998) . As the subunit composition of the G s protein that interacts with the b 3 -adrenoceptor of vascular myocytes has not been identi®ed, it can be postulated that this bg dimer may be unable to stimulate the Gbg-sensitive pathway leading to stimulation of L-type Ca 2+ channels. Activation of b-adrenoceptors is known to induce a relaxation in smooth muscle cells and several hypotheses have been proposed including Ca 2+ -dependent and Ca 2+ -independent mechanism. Although global increases in [Ca 2+ ] i regulate contraction, local Ca 2+ transients (Ca 2+ sparks) caused by opening of ryanodine-sensitive Ca 2+ release channels in the sarcoplasmic reticulum may activate K Ca channels in the surface membrane (Mironneau et al., 1996; Perez et al., 1999) leading to hyperpolarization and closing of voltage-dependent Ca 2+ channels (Knot & Nelson, 1998 currents, particularly in the voltage range between 720 and 0 mV (Arnaudeau et al., 1997) . In contrast, propagated Ca 2+ waves are obtained only when large (+10 mV) and durable (4200 ms) depolarizations are applied (Arnaudeau et al., 1997) . Preliminary results indicate that 1 mM CGP12177A and 5 mM forskolin increase the frequency of Ca 2+ sparks in portal vein myocytes held at 750 mV (F. Coussin and J. Mironneau, unpublished data), then promoting increased activation of K Ca channels, hyperpolarization and, ultimately, vasodilation. Therefore, it is proposed that the b 3 -adrenoceptor-mediated modulation of L-type Ca 2+ channels may be important in the regulation of smooth muscle tension.
In conclusion, the present study shows that in vascular myocytes activation of b 3 -adrenoceptors stimulates the L-type Ca 2+ channels though a Ga s -induced activation of the cyclic AMP/PKA pathway and the subsequent phosphorylation of the channels.
